Barraclough Katherine A, Isbel Nicole M, Staatz Christine E, Johnson David W
Department of Nephrology, University of Queensland at the Princess Alexandra Hospital, Brisbane, QLD 4102, Australia.
J Transplant. 2011;2011:750836. doi: 10.1155/2011/750836. Epub 2011 Jun 2.
The incidence of BK virus infection in kidney transplant recipients has increased over recent decades, coincident with the use of more potent immunosuppression. More importantly, posttransplant BK virus replication has emerged as an important cause of graft damage and subsequent graft loss. Immunosuppression has been accepted as a major risk for BK virus replication. However, the specific contribution of individual immunosuppressive medications to this risk has not been well established. The purpose of this paper is to provide an overview of the recent literature on the influence of the various immunosuppressant drugs and drug combinations on posttransplant BK virus replication. Evidence supporting the various immunosuppression reduction strategies utilised in the management of BK virus will also be briefly discussed.
近几十年来，肾移植受者中BK病毒感染的发生率有所上升，这与更强效免疫抑制药物的使用相一致。更重要的是，移植后BK病毒复制已成为移植物损伤及随后移植物丢失的一个重要原因。免疫抑制被认为是BK病毒复制的主要风险因素。然而，个别免疫抑制药物对这种风险的具体作用尚未完全明确。本文旨在概述近期有关各种免疫抑制药物及其组合对移植后BK病毒复制影响的文献。同时也将简要讨论支持在BK病毒管理中采用的各种免疫抑制减量策略的证据。
